Enzyme within cancer cells prevents immune system from fighting disease
An enzyme in cancer cells called aconitate decarboxylase (Acod1) appears to cause the release of short chains of amino acids, called peptides, that interfere with the way our bodies’ immune cells fight the disease, a new study by University of Notre Dame cancer biologist Zachary Schafer shows.
According to a research article in Cell Reports, cancer cells with high levels of Acod1, located in the mitochondria — the “powerhouses” of cells — were discovered to decrease the effectiveness of a certain type of cancer therapy called immune checkpoint inhibitor therapy. These drugs block protein “checkpoints” made by our immune system’s T cells and some cancer cells, preventing the T cells from killing the cancer. This type of cancer immunotherapy has proven to be effective in some cancers like melanomas, but not for cancers including prostate cancer, according to Schafer, the Coleman Foundation Associate Professor of Cancer Biology in the Department of Biological Sciences.
Previous research on Acod1, including another recent study in the lab of Xin Lu, the John M. and Mary Jo Boler Collegiate Associate Professor in the Department of Biological Sciences, has been focused on how Acod1 impacts the behavior and function of immune cells themselves.
“Our research shows that the cancer cells can use this enzyme as well. Surprisingly, Acod1 activity in cancer cells dampens the immune response, which is a really novel and exciting discovery,” said Schafer, who is affiliated with the Harper Cancer Research Institute.

As part of the experiments described in Schafer’s paper, researchers reduced the levels of Acod1 inside of prostate cancer cells. Next, the researchers introduced those altered cells into mouse models. Once the levels of Acod1 in the cancer cells were reduced, the immune checkpoint inhibitor therapy worked: The T cells rushed in to do their job, diminishing the cancer.
This project grew out of research in Schafer’s lab from 2018, when his group discovered a novel cancer cell death pathway involving changes in the mitochondria. Following that paper, his lab discovered that the cancer cells that were defective in this cell death pathway were also resistant to immune checkpoint inhibitors. He and collaborators then determined that, as a result of the significant changes in the mitochondria, Acod1 was responsible for the resistance to immune checkpoint inhibitors.
“That the cancer cells are better able to evade the immune response is totally dependent on this Acod1 enzyme,” Schafer said. “It’s definitely antagonizing the effect of the T-cells.”
Schafer and members of his lab are continuing to explore the effects of Acod1 for future studies. For instance, Schafer is interested in how Acod1 causes the production of the peptides, and he does not yet know the precise configuration of the amino acids in the peptides released by cancer cells with Acod1.
“We do not yet know how the T cells interact with these peptides, which is the other thing is that we are trying to figure out,” Schafer said.
This study was led by recent Notre Dame Ph.D. graduate James H. Schofield. In addition to Schafer and Schofield, other authors on the study are Emma Albano, Mark A. Hawk, Sean Murphy, Loan Duong, Sharif Rahmy,and Xin Lu, all from the University of Notre Dame, as well as Abigail E. Ellis, Joseph Longo, Russell G. Jones and Ryan D. Shelton of the Van Andel Institute, Grand Rapids, Michigan.
The paper was funded by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, the Coleman Foundation, and the Malanga Family Excellence Fund for Cancer Research, and the College of Science and Department of Biological Sciences at Notre Dame.
Originally published by science.nd.edu on May 16, 2024.
atLatest Research
- NSF CI Compass hosts FAIR Data Working Group to help major facilities, like MagLab, find data solutionsAs research facilities and their staff of researchers and scientists grapple daily with producing, storing, and preserving their petabytes of data for new discoveries and studies — others need to construct systems that can enable them to build on their findings. Within the data collected each day…
- Fatal school shootings have lasting impact on local economiesNew research from the University of Notre Dame offers the first large-scale empirical evidence that community anxiety caused by fatal school shootings can impact routine consumption behaviors like grocery shopping and dining out.
- Navigating the Waters of Peace: Challenges and Opportunities in the Implementation of Colombia's Peace AgreementNearly half the commitments outlined in Colombia's historic peace accord face significant challenges and may not happen in time unless policymakers make several key interventions, a new report from the University of Notre Dame warns. The report…
- Klau Institute’s Melsheimer Fellows learn about civil and human rights while serving South Bend communityOn a Wednesday evening in early April, a variation on the game of bingo was being played in the old St. Casimir Catholic School on the west side of South Bend. An instructor from One More Citizen, a nonprofit organization that offers free citizenship classes, was calling out questions from…
- Exploring Product-Market Fit: Inside the ESTEEM Unusual AcademyThis past year, several ESTEEM students had the opportunity to participate in the pilot of a new program: The ESTEEM Unusual Academy, led by Unusual Ventures Co-Founder and Managing Partner, John Vrionis.…
- Franco Institute announces inaugural Humanities Faculty Fellows and new Research Innovation CollaborativesThe Franco Family Institute for Liberal Arts and the Public Good, formerly the Institute for Scholarship in the Liberal Arts, continues its support of innovative research in the College of Arts & Letters with a new name and expanded mission. Seventeen faculty…